Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706623 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4ELMNACYP2C19MAPT | |
| SCHEMBL8344752 | 0.86 | SMN1; SMN2 (0.35) | SMN1; SMN2KDM4ELMNACYP2C19MAPT | |
| SCHEMBL8540868 | 0.78 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL4859696 | 0.77 | KDM4E (0.39) | SMN1; SMN2KDM4ELMNACYP2C19MAPT | |
| SCHEMBL2691041 | 0.77 | — | — | |
| SCHEMBL11837084 | 0.76 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL38953 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4ELMNACYP2C19TSHR | |
| SCHEMBL19261516 | 0.74 | KDM4E (0.39) | KDM4ELMNACYP2C19MAPTTSHR | |
| Hydrochloric Acid SCHEMBL20704047 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2KDM4ELMNACYP2C19TSHR | |
| Water SCHEMBL7733637 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2KDM4ELMNACYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4133263-B1 | CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES | ARES TRADING SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-20230152275-A1 | CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES | ARES TRADING S.A. (CH) | 2023-05-18 | — | — | US | disclosed |
| EP-4133263-A1 | CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES | Ares Trading S.A. (CH) | 2023-02-15 | — | — | EP | disclosed |
| EP-3892989-A1 | CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES | Ares Trading S.A. (CH) | 2021-10-13 | — | — | EP | disclosed |
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3686196-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-9738539-B2 | Separation and storage of fluids using ITQ-55 | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9688542-B2 | Separation and storage of fluids using ITQ-55 | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160008753-A1 | Separation and Storage of Fluids Using ITQ-55 | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160008753-A1 | Separation and Storage of Fluids Using ITQ-55 | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-01-14 | — | — | US | disclosed |
| US-7442687-B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442687-B2 | 2-polycyclic propynyl adenosine analogs having A2A agonist activity | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | IDO1, HDAC1, HDAC2 | SMN1; SMN2 4020/4885KDM4E 116/4885LMNA 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.